Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer. TAS-102 demonstrated improved survival and tolerability in patients with colorectal cancer and is currently approved by the FDA and marketed under the brand name …

  • 6 views
  • 23 Jan, 2021
  • 1 location
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory Rb Wild-Type Extensive SCLC

The purpose of this study is to: Test how well the study medicine Abemaciclib, a CDK4/6 inhibitor, works to shrink lung cancer tumors in the body. Test the safety of Abemaciclib when given to participants with small cell lung cancer (SCLC). Specifically, this study is looking at SCLC that has …

platinum-based chemotherapy
neutrophil count
measurable disease
alopecia
brain metastases
  • 3 views
  • 26 Jan, 2021
  • 1 location
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).

measurable disease
head and neck carcinoma
carcinoma
oropharyngeal
caries
  • 2 views
  • 19 Feb, 2021
  • 1 location
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

Lung adenocarcinoma with inactive LKB1 has emerged as a particularly aggressive form of lung cancer, with poor response to immune checkpoint inhibitors. Recent preclinical evidences have demonstrated that LKB1-inactive lung adenocarcinoma is characterized by specific metabolic vulnerabilities, which make it hypersensitive to energetic crisis. For instance, by inhibiting mitochondrial metabolism …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical …

  • 0 views
  • 31 Mar, 2021
  • 20 locations
Dose Escalation Versus Standard in Laryngopharyngeal Cancers

The primary objective of the study is to establish the safety of using a moderate escalation of radiotherapy dose in advanced/poor prognosis OPC and LH cancers receiving curative radiotherapy. The study will also explore the efficacy (improvement in complete response rates at 2 years) of dose escalation in intermediate and …

  • 2 views
  • 23 Jan, 2021
  • 1 location
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back (recurrent) or is stage IV. Talazoparib may stop the growth of tumor cells by blocking some …

hcv viral load
insulin
liver metastases
STK11
platinum-based chemotherapy
  • 33 views
  • 25 Jan, 2021
  • 250 locations
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Background Lung cancers with EGFR mutations may develop resistance to therapies targeting this protein by evolving/being transformed into small cell or neuroendocrine cancers. There are no standard treatments for it. Researchers want to see if a new combination of drugs can help. Objective To see if the combination of durvalumab …

  • 0 views
  • 12 Apr, 2021
  • 1 location
Bladder Cancer Adjuvant Radiotherapy Trial

Aim and objectives: This trial aims to evaluate the role of adjuvant radiotherapy following chemotherapy in patients with high-risk features on histo-pathology after radical surgery for transitional cell carcinoma of urinary bladder

transitional cell carcinoma of bladder
transitional cell carcinoma
bladder tumor
cystoprostatectomy
bladder cancer
  • 14 views
  • 23 Jan, 2021
  • 1 location
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The purpose of this study is to determine whether blocking a protein called poly (ADP-ribose) polymerase (PARP) with niraparib provides clinical benefit in patients with recurrent endometrial cancer, as well as to …

carcinosarcoma
measurable disease
corticosteroids
platinum-based chemotherapy
sarcoma
  • 87 views
  • 23 Jan, 2021
  • 7 locations